Treatment for Hypoglycemia

Recruiting · 18+ · All Sexes · Baltimore, MD

This study is evaluating whether a new glucose monitoring system can help reduce the number of hypoglycemic events in hospitalized veterans.

See full description

About the trial for Hypoglycemia

Eligible Conditions
Hypoglycemia · Diabetes Mellitus · Diabetes Mellitus, Type 2

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.

Control Group 1
POC (Point of Care)
Control Group 2
GTS (Continuous Glucose Monitoring)
POC (Point of Care)


This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
least 12 months of outpatient data and do not have any DM2 related hospitalizations during the 12 months prior to clinic visit were included in the study The study included veterans with DM2 who were managed with insulin (either basal bolus, basal only or basal with per os DM medications) and had at least 12 months of outpatient data show original
There is a very low risk of hypoglycemia associated with the use of Symlin. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Through study completion-hospitalization (average length of stay at the hospital of 4-6 days)
Screening: ~3 weeks
Treatment: Varies
Reporting: Through study completion-hospitalization (average length of stay at the hospital of 4-6 days)
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Through study completion-hospitalization (average length of stay at the hospital of 4-6 days).
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Hypoglycemia. Measurement will happen over the course of Through study completion-hospitalization (average length of stay at the hospital of 4-6 days).

Decrease in hypoglycemia during the hospitalization
GTS and the application of the hypoglycemia prevention protocol will lead to a decrease in hypoglycemia in the hospital

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is hypoglycemia?

Hypoglycemia presents as a constellation of symptoms that may range from mild and nonspecific to severe and life-threatening. Patients with unrecognised hypoglycemia must be promptly re-evaluated to identify the hypoglycemia triggers that should be addressed.

Anonymous Patient Answer

What are the signs of hypoglycemia?

Signs of hypoglycemia include headache, altered level of consciousness, dizziness and blurred vision. Dysautonomia, autonomic disfunction and alterations in cerebral oxygen delivery may also be evident in these patients. While most of such signs can be treated with the appropriate antihypoglycemic medication, severe cases of hypoglycemia may call for rapid treatment with glucose to restore blood glucose to its normal level. Hypoglycemia is also the cause of severe encephalopathy in diabetic patients. Therefore, hypoglycemia usually must be considered whenever severe neurological complications occur in diabetics.

Anonymous Patient Answer

How many people get hypoglycemia a year in the United States?

About 70 percent of adults and 55 percent of children with type 1 diabetes don't meet current treatment targets according to AACE/ADA guidelines. Most patients do not consult their care provider or do not comply with current hypoglycemic guidelines.

Anonymous Patient Answer

What are common treatments for hypoglycemia?

Hypoglycemia is common after gastric bypass, even in those with normal blood glucose levels. Most hypoglycemia occur in the early post-operative period. Although insulin is the most common treatment for hypoglycemia after gastric bypass, it is rarely sufficient to correct the fasting glucose level to normal.

Anonymous Patient Answer

Can hypoglycemia be cured?

Hypoglycemia cannot be cured. In patients with glucose counterregulatory deficiency, a normal glucose level may be an advantage. In patients with insulin-dependent diabetes and a good glucose control, hypoglycemia cannot be treated and may be even beneficial. In patients with non-insulin-dependent diabetes, with insulin resistance and a poor glucose control, hypoglycemia can be useful. For patients with a normal glucose level, insulin treatment should be tried instead of insulin-dependent glucocorticoid treatment. The treatment of hypoglycemic crises should be practiced with caution because relapse is common and unpredictable.

Anonymous Patient Answer

What causes hypoglycemia?

The current medical literature suggests that a variety of factors, such as hyperthyroidism, insulin deficiency, insulin resistance, congenital adrenal hyperplasia, certain types of tumors, excessive exercise and lack of sleep can contribute to hypoglycemia. Most of the hypoglycemia-causing factors that have been identified are associated with altered glucose metabolism.

Anonymous Patient Answer

What is the latest research for hypoglycemia?

Hypoglycemia remains a rare and often devastating problem. A common underlying cause is that the patient has a condition in which glycogen is not produced in the liver, which can occur in insulin-dependent diabetes as well as non-insulin-dependent diabetes.

Anonymous Patient Answer

Who should consider clinical trials for hypoglycemia?

Results from a recent paper showed that patients who have no prior history of hypoglycemia should have access to clinical trials in hypoglycemia. The study also supported the assumption that patients with hypoglycemia were already being treated for hypoglycemic effects of anti-diabetic drugs before entering the clinical trial. The study also supports the use of a clinical trial as the method of choice to manage hypoglycemia.

Anonymous Patient Answer

What are the latest developments in treatment for therapeutic use?

This article, and its recommendations, can be used to inform clinicians about the best treatment options for hypoglycemia. Treatments included in this article may decrease the need for hospitalization. These treatments are not cure, just ways to control problems with hypoglycemia.

Anonymous Patient Answer

Is treatment typically used in combination with any other treatments?

Data from a recent study of the present study suggest that an effective treatment has been chosen, although the reason for choosing it and in what proportion of patients, is unclear and requires further investigation.

Anonymous Patient Answer

Have there been any new discoveries for treating hypoglycemia?

The recent advancements involve the administration of insulin and/or dextrose in combination with epinephrine, which can be an effective alternative in treatment of hypoglycemia. Future advances include the new therapeutic approaches for the treatment of hypoglycemia. Further studies with larger samples and long-term follow-ups need to be developed to explore the effects of these therapeutic approaches upon the development and progression of diabetes over the course of a lifetime.

Anonymous Patient Answer

Is treatment safe for people?

The risk of diabetes treatment is not a key factor in treating physicians' decisions on diabetes treatment. Many physicians are skeptical about the medical benefits of oral glucose lowering agents and insulin and do not give this type of treatment as first-line therapy to the majority of their patients with diabetes. In light of our findings, it is important for people with Type 1 diabetes to be informed about the risks and benefits of diabetes treatment, so they can make their own well-informed decisions about treatment.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Hypoglycemia by sharing your contact details with the study coordinator.